Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide Dosing in Transfusion Dependent Beta Thalassemia
NCT06490627Phase 2Recruiting
- Sponsor
- National Institute of Blood and Marrow Transplant
- Start
- Apr 2024
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of thalidomide in beta thalassemia, sponsored by National Institute of Blood and Marrow Transplant. Started Apr 2024; status: recruiting.
02
Drugs
thalidomide
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on NCT06490627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06490627.